Press Releases

Biocon Biologics  /  Press Releases

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business

  • Posted by: Biocon Biologics

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%

  • Posted by: Biocon Biologics

Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022

  • Posted by: Biocon Biologics

Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine  

  • Posted by: Biocon Biologics

Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan

  • Posted by: Biocon Biologics

Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility

  • Posted by: Biocon Biologics

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%

  • Posted by: Biocon Biologics

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre

  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada

  • Posted by: Biocon Biologics

Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%

  • Posted by: Biocon Biologics
Share